KORU Medical Systems, Inc. (KRMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 12, 2025, announces the financial results for the third fiscal quarter ended September 30, 2025. The filing also includes updated financial guidance for the fiscal year ending December 31, 2025. A related conference call was scheduled for November 12, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
The Company utilizes the following non-GAAP measures to supplement GAAP results:
- Adjusted EBITDA: Defined as net income/loss before interest, depreciation, amortization, reorganization charges, taxes, and stock-based compensation.
- Adjusted Diluted EPS: Adjusted for interest, depreciation, amortization, reorganization charges, taxes, and stock-based compensation to reflect ordinary operations.
Material Changes and Guidance
The Company has issued updated financial guidance for the full fiscal year 2025. The filing does not detail specific material changes versus the prior period or the specific nature of the guidance update, as this information resides in the attached press release (Exhibit 99.1).
Management Commentary and Risks
Management emphasizes that non-GAAP measures are intended to enhance investor understanding of ongoing operational performance and cash flow generation capacity. The filing includes standard cautions that non-GAAP measures may differ from those used by other companies and should not be viewed as replacements for GAAP measures. A reconciliation of GAAP to non-GAAP results is provided in Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue, net income, and cash flow figures.
- Verify the specific details of the updated full-year 2025 guidance provided in the press release.
- Examine the reconciliation of GAAP to non-GAAP measures to understand the adjustments made to EBITDA and EPS.
- Confirm the conference call transcript for management's qualitative commentary on the results and outlook.